New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP

Swedish Life science company OnDosis and German B2B pharmaceutical company TIEFENBACHER GROUP initiate four new innovative development projects targeting ADHD, rare diseases, and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine. TIEFENBACHER GROUP is a pioneering healthcare company with innovative and best-in-class solutions along the entire pharmaceutical development value chain. The company’s vision is to improve patients’ lives by making a difference in tomorrow’s health. An idea that corresponds well with how OnDosis wants to revolutionize how patients take their medicines. “It feels fantastic to expand our existing collaboration with several new projects,” says Dr. Kristian Ruepp, Joint Managing Director, TIEFENBACHER GROUP. Last year, the two companies began cooperating on an ADHD treatment that has already received attention in the USA. As an example, the OnDosis drug/device for ADHD was highlighted during APSARD, the annual general meeting of The American Professional Society of ADHD and Related Disorders.

“Whilst our first ADHD project fast approaches final stages of development, we are thrilled to partner up with TIEFENBACHER for no less than four more projects that will greatly expand our portfolio,” says Martin Olovsson, CEO OnDosis. “Some of the critical and heart-warming targets include helping those with serious rare diseases, and patients that have undergone an organ transplant. Two patient groups where finely tuned and individualized doses of the prescribed medications are critical to outcomes and necessary to for patients to live a better everyday life.” The partnership aims to develop and commercialize products in the intersection between traditional drug-based medicine and digital therapeutics. The five products developed are planned for launch 2023 and onwards. The team at OnDosis consists of experts in developing and designing proprietary solutions, including intuitive, user-friendly, and connected devices that deliver medicine and enables digital solutions to be integrated. As a result, each patient’s specific needs can be met with individualized doses that the patient or the doctor can adjust should the need arise. The collection of data on dosing linked to outcomes open up a new field of a closed loop disease management. Ultimately, the goal is to achieve algorithm-based
dosing through predictive modeling leading to personalized treatments. Another novelty is to dispense the drugs as pellets instead of pills or capsules, making them easier to consume.

TIEFENBACHER GROUP has significant expertise and experience in developing pharmaceuticals across all stages of development. Their expertise guarantees efficient development of medicines in a form that allows individual dosing whilst meeting the most rigorous quality and safety standards. Also, TIEFENBACHER’s leading competence within supply chain and B2B commercialization will be instrumental when the first products developed by Tiefenbacher and OnDosis reach the market in 2023-2024. “One of our key focus areas is what we call ‘Beyond Imagination’, and OnDosis is the right partner when going there. Together, we will make a real difference when it comes to optimizing the effects of the medicine people take,” says Kristian Ruepp. “We want to give people a chance to live the life they deserve. For many, this is only possible with the right dose of their prescribed medication. In collaboration with Tiefenbacher, we have every chance to fulfill this vision,” Martin Olovsson concludes.

For further information around pharmaceuticals or other worldwide health solutions please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu